Worldwide, the entire month of June is dedicated to honoring cancer survivors. In most cancer survivors, the disease leaves a sense of responsibility, i.e., to raise awareness about cancer as a preventable disease.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
The Hindu Business Line I Kochi I Updated on October 28, 2021: A slew of marquee backers including the Tata group are supporting Karkinos Healthcare’s push to provide affordable cancer care. The comprehensive oncology platform set up with an investment of ₹110 crore has started off from Kerala.
Friends, this is breast cancer awareness month and this is part 1 of the 3-part series of articles I decided to write for the benefit of team Karkinos, nonmedical colleagues, and friends. Education, they say, starts at home as we expand our horizons to go to the world. Part 2 deals with the changing spectrum in breast cancer and Part 3 – the challenges in breast cancer and overcoming them.
New treatment interventions and progress in understanding the biology of cancer truly changed the overall prognosis and survival indices in breast cancer.
We as a community need to work together and not just brace it but contribute to the dawn of new innovative and creative thoughts to cancel and checkmate cancer and overcome the challenges for a better tomorrow.
This strategic collaboration will enable continued innovation in cancer care with the goal of transforming cancer care in India and abroad.
Together, Karkinos Healthcare and GenWorks will provide primary screening through HPV DNA tests, and confirmatory diagnoses through colposcopy at the clinics and hospitals of the partner gynecologists.
Karkinos Healthcare has laid down its primary goal to shift the focus of cancer care towards the left side of the spectrum, i.e., early detection and infuse a behavioral shift among citizens in their attitude from illness to wellness.
Karkinos Healthcare closed a funding round with the Tatas Group drawing an investment of Rs 110 crores. Tata Group has disbursed Rs. 35 crores immediately and the rest of the funding is expected to be disbursed in tranches in the coming months.
By Dr. Moni Abraham Kuriakose – Medical Director, Karkinos Healthcare & CEO, Karkinos Healthcare, Kerala
The core objective of Karkinos Healthcare is to create an up-to-date dynamic knowledge base and curate that knowledge to distribute, democratize, and integrate…
By Dr. R. Sankaranarayanan – Director, Preventive Oncology, Karkinos Healthcare
Cancer ― the Emperor of all Maladies ― is one of the greatest health challenges to mankind and is one of the leading causes of death across the globe. I have personally seen the disease to devastate families and to drag people to extreme poverty.
KARKINOS HEALTHCARE (KH) is desirous to build an end-to-end technology driven oncology focused managed healthcare platform where almost no person is deprived of care either by lack of access or affordability.
